CS
SPRY icon

Credit Suisse’s ARS Pharmaceuticals SPRY Stock Holding History

Credit Suisse’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$302K Hold
29,507
– – ﹤0.01% 2823
2023
Q4 		$162K Sell
29,507
-3,772
-11% -$16.5K ﹤0.01% 3002
2023
Q3 		$126K Buy
33,279
+1,385
+4% +$9.09K ﹤0.01% 3082
2023
Q2 		$214K Buy
+31,894
New +$213K ﹤0.01% 3082
2022
Q3 		– Sell
-11
Closed – – 4269
2022
Q2 		$0 Buy
+11
New +$38 ﹤0.01% 4288
2021
Q3 		– Sell
-7,301
Closed -$226K – 4530
2021
Q2 		$226K Buy
+7,301
New +$234K ﹤0.01% 4239

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's SPRY Position: Q1 2024 in Review

Credit Suisse held its ARS Pharmaceuticals (SPRY) position steady in Q1 2024 at 29,507 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #2823.

Credit Suisse first reported a position in SPRY in Q2 2021 and has held it in 6 quarters since. 113 funds tracked by Wall St. Rank hold SPRY as of Q1 2024.

  • Credit Suisse held 29,507 shares of ARS Pharmaceuticals worth $302K as of Q1 2024.
  • Credit Suisse left its ARS Pharmaceuticals share count unchanged in Q1 2024.
  • ARS Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2823 holding.
  • Credit Suisse first reported a position in ARS Pharmaceuticals in Q2 2021 and has held it in 6 quarters since.
  • 113 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.